Skip to main content
Explore URMC
menu

Deepinder Pal Singh, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Imaging Sciences, Radiation Oncology

Biography

Cancer is one of the most challenging medical problems, especially head and neck and lung cancers. I am very well trained, well read and highly experienced. I am also a compassionate and caring physician.

I provide my patients with comprehensive medical care including personalized, curative intent treatment. Since my patients deserve only the best, they can be confident knowing they will receive excellent medical care from me. My areas of expertise include stereotactic body radiation therapy and brachytherapy for lung cancers, as well as treating nasopharyngeal, oropharyngeal, oral cavity, laryngeal and hypopharyngeal cancers.

Conditions I Treat:

- Lung cancer
- Head and neck cancers

Credentials

Education

1981
MBBS | Indira Gandhi Medical College, Shimla (India)

Post-doctoral Training & Residency

07/01/2005 - 06/30/2009
Residency in Radiation Oncology at University of Rochester Medical Center

07/01/2003 - 06/30/2005
Fellowship in Radiation Oncology at University of Rochester Medical Center

04/02/2001 - 06/30/2003
Fellowship at University of Rochester Medical Center

09/17/1986 - 12/16/1989
Fellowship at Postgraduate Institute of Medical Education & Research

07/01/1984 - 06/30/1986
Residency at Postgraduate Institute of Medical Education & Research

05/23/1982 - 05/22/1983
Residency at Indira Ghandi Medical College (India)

05/08/1981 - 05/07/1982
Internship at Indira Ghandi Medical College (India)

VIEW ALL expand_more

Awards

2020
Certificate of Appreciation
Sponsor: Department of Radiation Oncology Nurses
Location: Rochester, NY

2019 - 2020
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

2016 - 2019
Bronze Star
Sponsor: University of Rochester Medical Center
Location: Rochester, NY

2012 - 2013
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

VIEW ALL expand_more

Clinical Trials

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (NRG-HN005)

Lead Researcher: Deepinder Pal Singh

This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its growth and may not have spread to other parts of the body (early-stage), and is not associated with smoking. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to see if a reduced dose of radiation therapy and nivolumab works as well as standard dose radiation therapy and cisplatin in treating patients with oropharyngeal cancer.

View Study Details

Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early- Stage Non-Small-Cell Lung Cancer: A Prospective Randomized Phase II Study

Lead Researcher: Deepinder Pal Singh

This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be randomly assigned to either the 3 Fraction or 5 Fraction schedule of radiation. After patients complete radiation treatment, they will follow up with their radiation oncologist.

View Study Details

Publications

Journal Articles

2021
Singh DP; Aujla K; Nead M; Bylund K. "Radiologically occult lung cancer curatively treated with high-dose rate endobronchial brachytherapy". J Clin Imaging Sci. 2021; 11: 45.

2021
Webster M; Tanny S; Joyce N; Herman A; Chen Y; Milano M; Usuki K; Constine L; Singh D; Yeo I. "New dosimetric guidelines for linear Boltzmann transport equations through comparative evaluation of stereotactic body radiation therapy for lung treatment planning". J Appl Clin Med Phys. 2021; 22(12): 115-124.

2021
Cummings MA; Ma SJ; Van Der Sloot P; Milano MT; Singh DP; Singh AK. "Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry". Ann Transl Med. 2021; 9(4): 284.

Books & Chapters

2011
Chapter Title: Translational Research in Lung Cancer
Book Title: Advances in Radiation Oncology in Lung Cancer
Author List: Singh D; Bylund K; Chen Y
Edited By: Jeremic B
Published By: Springer-Verlag GmbH 2011 in Heidelberg

2000
Chapter Title: Carcinoma of the nasopharynx
Book Title: Textbook of Radiation Oncology: Principles and Practice
Author List: Sharma SC, Singh DP, Jalali R
Published By: Churchill Livingstone 2000

VIEW ALL PUBLICATIONS